ICN Pharmaceuticals Inc. has again extended its offer to buy drug-maker Ribapharm Inc. until 1 August 2003 and emphasized that shareholders should not expect its $168 million bid to be sweetened. As of July 29, when the offer was set to expire, about 7.7 million Ribapharm shares were tendered for the offer of $5.60 a Read more about ICN Extends Ribapharm Offer, Says No Sweetener[…]
Cognis has announced that they have signed an agreement effective Sept. 1, 2002 which grants Cognis an exclusive license in the Key Markets, under Natural‘s Conjugated Linoleic Acid (CLA) intellectual property, technology, and know-how, and an exclusive license for the use of the Tonalin trademark. Conjugated Linoleic Acid (CLA) has been shown to be a Read more about Cognis Signs Exclusive Licensing Agreement With Natural ASA[…]
Anadys Pharmaceuticals, Inc. and Sequoia Sciences, Inc. have entered into a drug discovery collaboration to identify novel anti-infectives. This partnership will harness Sequoia’s unique library of compounds isolated from natural products using the fully integrated drug discovery capabilities of Anadys. Under the terms of the agreement, Anadys will deploy its proprietary screening technologies uHTS-ATLAS and Read more about Anadys And Sequoia Sciences Announce Drug Discovery Collaboration[…]
Epimmune Inc. has entered into an evaluation and license option agreement with Immuno-Designed Molecules, S.A. (IDM) for certain cancer antigens for use in IDM’s ex vivo cancer therapy program. Under the terms of the agreement, IDM will have 120 days from the date of the option agreement to evaluate the epitopes and exercise its option Read more about Epimmune And Immuno-designed Molecules Agree License Option[…]
Nabi have signed two international distribution agreements for Nabi-HB [Hepatitis B Immune Globulin (Human)] with Biotech Medical Corporation of Malaysia and Innovative Biotech PTE LTD, a corporation of the Republic of Singapore. Global expansion of Nabi-HB continues to be a key objective for Nabi Biopharmaceuticals, according to David Gury, chairman, president and CEO. “Our agreements Read more about Nabi Expands Global Presence[…]
Discovery Laboratories, Inc. and CollaGenex Pharmaceuticals, Inc. announced a research collaboration to evaluate the combination of their platform technologies for the development of novel respiratory disease therapeutics. The two companies will collaborate on the preclinical evaluation of an aerosolized formulation of Discovery’s humanized lung surfactants combined with CollaGenex‘s IMPACS (Inhibitors of Multiple Proteases and CytokineS) Read more about Discovery And Collagenex Collaborate[…]
Arriva Pharmaceuticals, Inc. has signed an agreement to develop and commercialise the synthetic matrix metalloprotease inhibitor (MMPI) Ilomastat for the treatment of inflammatory respiratory diseases. “This is a further demonstration of our strategy, which aims to build a product pipeline in protease inhibitors and respiratory diseases,” said Martin Preuveneers, Ph.D., Chairman and CEO of Arriva. Read more about Arriva Signs Agreement For Respiratory Disease Treatment[…]
Theratechnologies has signed another license agreement with Bioartificial Gel Technologies (B.A.G.Tech), extending the license granted in 1999 relating to its extraction process and the applications of its platelet-derived growth factor cocktail. The license agreement announced today covers their in vivo use for therapeutic purposes in the areas of tissue engineering and wound healing. “We are Read more about Theratechnologies Signs Further License Agreement With B.A.G.Tech[…]
Inex Pharmaceuticals Corporation has formed a joint venture with Elan Corporation, plc for the development and commercialisation of INEX’s lead product, Onco TCS, now being evaluated in human clinical trials as a treatment for a number of cancers. INEX and Elan have both contributed assets to the joint venture including worldwide rights to Onco TCS Read more about Inex Forms Joint Venture With Elan[…]
Microcide Pharmaceuticals, Inc. has entered into a research collaborative agreement with Discovery Partners International, Inc., to optimise the drug-like qualities of Microcide’s recently discovered broad-spectrum antifungal compound series. Using Microcide’s proprietary microbial genomics VALID System, the Company has discovered and developed a series of promising antifungal compounds to the point of lead optimisation. Members of Read more about Microcide Signs Research Collaboration[…]